Literature DB >> 8552400

Mutations of the p16 gene in gliomas.

A P Kyritsis1, B Zhang, W Zhang, M Xiao, H Takeshima, M L Bondy, J E Cunningham, V A Levin, J Bruner.   

Abstract

In the present study we investigated the frequency of p16 gene exon 2 mutations in 35 malignant gliomas, using either direct sequencing of the PCR products or cloning into the pCRII vector and sequencing of the cloned PCR products. No mutations were detected during direct sequencing of the PCR products. However, after sequencing of individual clones, we found multiple mutations in 5 tumors involving codons 73(GCC to ACC, Ala to Thr), 76 (GCC to GTC, Ala to Val), 85(GCT to ACT, Ala to Thr), 98(CAC to TAC, His to Tyr), 102 (GCG to GTG, Ala to Val), 106 (GTG to ATG, Val to Met), 107 (CGC to TGC, Arg to Cys), 127 (GCA to GTA, Ala to Val), 128 (CGG to TGG, Arg to Trp) and 136 (GGC to GAC, Gly to Asp). Mutations were found only in glioblastomas and were either C to T or G to A transitions. Each mutation was detected in a small percentage of tumor cells (1.3-22%) using individual colony sequencing and southern hybridization with mutant oligonucleotides, consistent with the heterogenous cell population of glioblastomas. The presence of p16 gene mutations only in glioblastomas suggests that they are late events in glioma development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8552400

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  GRIM-19 and p16(INK4a) synergistically regulate cell cycle progression and E2F1-responsive gene expression.

Authors:  Peng Sun; Shreeram C Nallar; Abhijit Raha; Sudhakar Kalakonda; Chidambaram N Velalar; Sekhar P Reddy; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

Review 3.  Delivery of cell cycle genes to block astrocytoma growth.

Authors:  J Fueyo; C Gomez-Manzano; T J Liu; W K Yung
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.

Authors:  H Miettinen; J Kononen; P Sallinen; H Alho; P Helen; H Helin; H Kalimo; L Paljärvi; J Isola; H Haapasalo
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

Review 5.  Inherited predisposition to glioma.

Authors:  Athanassios P Kyritsis; Melissa L Bondy; Jasti S Rao; Chrissa Sioka
Journal:  Neuro Oncol       Date:  2009-11-23       Impact factor: 12.300

Review 6.  The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.

Authors:  Swati Mahajan; Iman Dandapath; Ajay Garg; Mehar C Sharma; Vaishali Suri; Chitra Sarkar
Journal:  Lab Invest       Date:  2022-01-14       Impact factor: 5.662

7.  Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.

Authors:  David A Solomon; Jung-Sik Kim; Sultan Jenkins; Habtom Ressom; Michael Huang; Nicholas Coppa; Lauren Mabanta; Darell Bigner; Hai Yan; Walter Jean; Todd Waldman
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients.

Authors:  M K Sibin; Dhananjaya I Bhat; Ch Lavanya; M Jeru Manoj; S Aakershita; G K Chetan
Journal:  Tumour Biol       Date:  2013-09-25

Review 9.  Genome-Wide Association Studies in Glioma.

Authors:  Ben Kinnersley; Richard S Houlston; Melissa L Bondy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-01-30       Impact factor: 4.254

10.  Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.

Authors:  M Sartor; H Steingrimsdottir; F Elamin; J Gäken; S Warnakulasuriya; M Partridge; N Thakker; N W Johnson; M Tavassoli
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.